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39% of patients by 6 months (6). A single-center
Italian study also reported that 67% of patients with nonischemic cardiomyopathy treated with GDMT (87% beta-blocker and 95% RAI usage rates) no longer met criteria for a primary prevention ICD (7).
In the paper by Roth et al. Of greater concern is that medical providers may not be prescribing GDMT and titrating doses appropriately in eligible patients with HFrEF. Despite the promotion in professional society guidelines of gfonarow@mednet.ucla.edu.
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